Option chain shows key data for Svenska Handelsbanken's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Svenska Handelsbanken.

Svenska Handelsbanken (OTC:SVNLY) Stock, Option Chain

Svenska Handelsbanken

SVENSKA HANDELS ADR

Handelsbanken is one of the largest Swedish banks with significant exposure to the Swedish mortgage market; about 44% of total loans are tied to the Swedish real estate market. Outside of Sweden, the bank operates primarily in the U.K. and Netherlands. Handelsbanken generates about three fourths of its income through its interest spread-based business, including mortgages, household loans, and corporate loans to large and small enterprises.

Biotech

News

Penny Stocks

Global

Media

General

ALXN

GILD

SVNLY

Stockholm headquartered private equity group EQT AB will buy Swedish pharma company Recipharm AB for $2.1 billion, according to company&#39;s 

Private Equity EQT Offers To Acquire Swedish Pharma Recipharm For $2.1B

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

AAWW

ACOR

AGGG

AMCX

AMKAF

ARLP

ATRO

ATTO

AVLIF

BACHF

BBBY

BHKLY

BIREF

BJCHF

BMRN

BMWYY

BLUE PRISM GROUP PLC ORD by Blue Prism Group PLC

BPRMF

BRTX

CAKE

CARB

CATC

CDEV

CEQXF

CFWFF

CGNSF

CHMJF

COMM

CPCAY

CRTPF

CTPCY

CTTAY

CVET

CWYCY

CYCC

DDAIF

DLAKY

DMLRY

DNKEY

DSEEY

DSFGY

DSITF

EBIX

ELIO

EONGY

ESVIF

ETRN

FOCS

FORR

FUPBY

GBHL

GFSZF

GFSZY

GHSI

GIII

GNFT

GVHIB

HDSN

HNRG

HSNGY

HUSKF

IBKR

IDCBY

IDSA

IFRX

ILUS

INAP

INPX

JBFCF

JBFCY

Stocks That Hit 52-Week Lows On Thursday

Stocks That Hit 52-Week Lows On Wednesday

SVENSKA HANDELSBK UNS/ADR by Svenska Handelsbanken AB PUBL

Svenska Handelsbanken AB

Svenska Handelsbanken (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SVNLY#OTC">SVNLY</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-02-07. Here's what investors need to know before the announcement.
Analysts estimate that Svenska Handelsbanken will report an earnings per share (EPS) of $1.57. 
Svenska Handelsbanken bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $1.60, which was followed by a 0.99% increase in the share price the next day.
Here's a look at Svenska Handelsbanken's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.79</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.19</td>
<td>0.17</td>
<td>0.16</td>
<td>0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.99%</td>
<td>0.22%</td>
<td>1.24%</td>
<td>2.94%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of Svenska Handelsbanken were trading at $5.205 as of February 02. Over the last 52-week period, shares are up 9.12%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SVNLY/earnings">To track all earnings releases for Svenska Handelsbanken visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Svenska Handelsbanken's Earnings: A Preview

Svenska Handelsbanken (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SVNLY#OTC">SVNLY</a>) is set to give its latest quarterly earnings report on Wednesday, 2022-10-19. Here's what investors need to know before the announcement.
Analysts estimate that Svenska Handelsbanken will report an earnings per share (EPS) of $1.23. 
Svenska Handelsbanken bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Here's a look at Svenska Handelsbanken's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2022</th>
<th>Q1 2022</th>
<th>Q4 2021</th>
<th>Q3 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.11</td>
<td>0.15</td>
<td>0.15</td>
<td>0.15</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.41%</td>
<td>5.28%</td>
<td>-3.51%</td>
<td>-0.17%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of Svenska Handelsbanken were trading at $4.21 as of October 17. Over the last 52-week period, shares are down 26.68%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SVNLY/earnings">To track all earnings releases for Svenska Handelsbanken visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Svenska Handelsbanken

Svenska Handelsbanken (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SVNLY#OTC">SVNLY</a>) is set to give its latest quarterly earnings report on Tuesday, 2022-10-18. Here's what investors need to know before the announcement.
Analysts estimate that Svenska Handelsbanken will report an earnings per share (EPS) of $1.23. 
Svenska Handelsbanken bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Here's a look at Svenska Handelsbanken's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2022</th>
<th>Q1 2022</th>
<th>Q4 2021</th>
<th>Q3 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.11</td>
<td>0.15</td>
<td>0.15</td>
<td>0.15</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.41%</td>
<td>5.28%</td>
<td>-3.51%</td>
<td>-0.17%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of Svenska Handelsbanken were trading at $4.015 as of October 14. Over the last 52-week period, shares are down 32.64%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SVNLY/earnings">To track all earnings releases for Svenska Handelsbanken visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Svenska Handelsbanken

Stockholm headquartered private equity group&nbsp;EQT AB&nbsp;will buy Swedish pharma company&nbsp;Recipharm AB&nbsp;for $2.1 billion, according to company&#39;s <a class="editor-rtfLink" href="https://www.eqtgroup.com/other/pe-bidpage1/" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">press release</a>.
The transaction will be routed through&nbsp;Roar BidCo&nbsp;AB,&nbsp;a limited liability company established on Nov. 10, 2020, wholly-owned by EQT.
Why Does It Matter: The purchased consideration is fixed at 220 SEK per share in cash, a 23% premium on Recipharm closing price in the Stockholm Stock Exchange Friday. The convertible bondholders will be paid SEK 1,427 for every SEK 1,000 held as the principal amount.
<a class="editor-rtfLink" href="https://www.bloomberg.com/news/articles/2020-12-14/eqt-offers-to-buy-recipharm-of-sweden-in-2-1-billion-deal?sref=TBDibEcD" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">Bloomberg</a>&nbsp;cited Peter Sehested, an analyst from the Swedish consumer bank&nbsp;Svenska Handelsbanken AB&nbsp;saying that the offer price is lower compared to the other deals in the pharma industry. For the deal to follow through, 90% of shareholders are required to vote in favor.
Why Does It Matter: Post-acquisition, Roar Bidco will hold 25.7% ownership in Recipharm with 74.3% voting rights through Recipharm Board Chairman Lars Backsell and Recipharm CEO Thomas Eldered. Both members are participating with EQT.
The pharmaceutical industry is witnessing a wave of consolidation by way of mergers and acquisitions.
On&nbsp;Saturday,&nbsp;AstraZeneca PLC&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/azn#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">AZN</a>)&nbsp;<a class="editor-rtfLink" href="http://www.benzinga.com/general/biotech/20/12/18763050/astrazeneca-to-buy-rare-disease-specialist-drugmaker-alexion-for-39-billion" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">agreed</a>&nbsp;to a $39 billion acquisition deal with&nbsp;Alexion Pharmaceuticals Inc&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/alxn#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">ALXN</a>) in a cash and stock deal.
Last week,&nbsp;Gilead Sciences Inc&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/gild#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">GILD</a>) also&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/20/12/18734168/merger-thursday-gilead-buys-german-drug-company-aytu-neos-all-stock-deal-boehringer-picks-up-nbe-" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">announced</a>&nbsp;a $1.4 billion agreement to buy German drugmaker MYR Pharmaceuticals.

<h3>Companies Reporting Before The Bell</h3>
&bull; Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="/stock/GS#NYSE">GS</a>) is estimated to report quarterly earnings at $3.78 per share on revenue of $9.73 billion.
&bull; ASML Holding Inc. (NASDAQ:<a class="ticker" href="/stock/ASML#NASDAQ">ASML</a>) is estimated to report quarterly earnings at $1.45 per share on revenue of $3.88 billion.
&bull; UnitedHealth Group Inc. (NYSE:<a class="ticker" href="/stock/UNH#NYSE">UNH</a>) is expected to report quarterly earnings at $5.18 per share on revenue of $63.43 billion.
&bull; Bank of New York Mellon Inc. (NYSE:<a class="ticker" href="/stock/BK#NYSE">BK</a>) is estimated to report quarterly earnings at $0.91 per share on revenue of $3.89 billion.
&bull; PNC Financial Services Gr Inc. (NYSE:<a class="ticker" href="/stock/PNC#NYSE">PNC</a>) is expected to report quarterly earnings at $0.51 per share on revenue of $4.11 billion.
&bull; Progressive Inc. (NYSE:<a class="ticker" href="/stock/PGR#NYSE">PGR</a>) is estimated to report quarterly earnings at $1.74 per share on revenue of $9.72 billion.
&bull; U.S. Bancorp Inc. (NYSE:<a class="ticker" href="/stock/USB#NYSE">USB</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $5.54 billion.
&bull; Temenos Inc. (OTC:<a class="ticker" href="/stock/TMSNY#OTC">TMSNY</a>) is expected to report earnings for it&#39;s second quarter.
&bull; Infosys Inc. (NYSE:<a class="ticker" href="/stock/INFY#NYSE">INFY</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $2.94 billion. 
&nbsp;
<h3>Companies Reporting After The Bell</h3>
&bull; Alcoa Inc. (NYSE:<a class="ticker" href="/stock/AA#NYSE">AA</a>) is expected to report quarterly loss at $0.54 per share on revenue of $2.11 billion.
&bull; Sleep Number Inc. (NASDAQ:<a class="ticker" href="/stock/SNBR#NASDAQ">SNBR</a>) is estimated to report quarterly loss at $0.80 per share on revenue of $216.36 million.

Comments

Svenska Handelsbanken

Svenska Handelsbanken (SVNLY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga